Overview of Ertugliflozin

Introduction

Despite the availability of 12 different classes of medications, many people with type 2 diabetes struggle to maintain glycemic control (1). Among the many new antidiabetic medications to have emerged in recent years, sodium–glucose cotransporter 2 (SGLT2) inhibitors have proved to be a particularly effective oral treatment for these patients (2). Since the approval of the first drug in this class, canagliflozin, by the U.S. Food and Drug Administration (FDA) in March 2013, a total of four SGLT2 agents have become available (both as single and fixed-dose combination formulas) (1). In 2017, an estimated 1.7 million patients received a dispensed prescription for an SGLT2 inhibitor from U.S. outpatient retail pharmacies (2). Ertugliflozin is the newest agent among these, having received FDA approval in December 2017 (3).